US Capitol Capsule: Industry attack on 340B 'unsubstantiated,' safety net group charges
This article was originally published in Scrip
The lobbying groups representing big pharma, biotechs, chain drug stores and pharmacy benefit managers went on the attack last week against the US 340B drug-pricing program and the safety net hospitals and other facilities that benefit from it – charging that the program has "departed significantly" from its goal of ensuring uninsured indigent outpatients are receiving access to low-cost drugs.
You may also be interested in...
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.